Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.

Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, Prochazka V, Pytlik R, Pirnos J, Duras J, Mocikova H, Bortlicek Z, Kopalova N, Mayer J, Trneny M.

Ann Hematol. 2019 May 8. doi: 10.1007/s00277-019-03694-y. [Epub ahead of print]

PMID:
31065733
2.

Chronic Benign CD8+ Proliferation: A Rare Affection that Can Mimic a Lymphoma Relapse.

Osovská M, Janíková A, Křen L, Marečková A.

Case Rep Hematol. 2019 Mar 5;2019:4932616. doi: 10.1155/2019/4932616. eCollection 2019.

3.

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.

Mareckova A, Malcikova J, Tom N, Pal K, Radova L, Salek D, Janikova A, Moulis M, Smardova J, Kren L, Mayer J, Trbusek M.

Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542144. [Epub ahead of print]

PMID:
30626249
4.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M.

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13. No abstract available.

PMID:
30474171
5.

New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.

Devan J, Janikova A, Mraz M.

Semin Oncol. 2018 Oct;45(5-6):291-302. doi: 10.1053/j.seminoncol.2018.07.005. Epub 2018 Oct 23. Review.

PMID:
30360879
6.

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A, Mraz M.

Blood. 2018 Nov 29;132(22):2389-2400. doi: 10.1182/blood-2018-06-855502. Epub 2018 Sep 13.

PMID:
30213873
7.

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.

Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, Duras J, Mocikova H, Trneny M.

Leuk Res. 2018 Oct;73:29-38. doi: 10.1016/j.leukres.2018.08.019. Epub 2018 Aug 31.

PMID:
30195062
8.

Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry.

Obr A, Prochazka V, Papajik T, Klener P Jr, Janikova A, Salek D, Belada D, Pytlík R, Sykorova A, Mocikova H, Simkovic M, Campr V, Dlouha J, Furst T, Trněný M.

Leuk Lymphoma. 2019 Mar;60(3):748-755. doi: 10.1080/10428194.2018.1508672. Epub 2018 Sep 6.

PMID:
30188225
9.

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.

Walewski J, Paszkiewicz-Kozik E, Borsaru G, Hellmann A, Janikova A, Warszewska A, Mais A, Ammendola A, Herz T, Krauss B, Henning SW.

Leuk Lymphoma. 2019 Mar;60(3):675-684. doi: 10.1080/10428194.2018.1492122. Epub 2018 Aug 30.

PMID:
30160566
10.

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M.

Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13.

PMID:
30129045
11.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

12.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064. Review.

13.

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.

PMID:
29318369
14.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

PMID:
29083050
15.

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.

Procházka V, Papajík T, Janíková A, Belada D, Kozák T, Šálek D, Sýkorová A, Móciková H, Campr V, Dlouhá J, Langová K, Fürst T, Trněný M.

Leuk Lymphoma. 2017 Mar;58(3):601-613. doi: 10.1080/10428194.2016.1213834. Epub 2016 Sep 25.

PMID:
27666539
16.

Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.

Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M; Czech Lymphoma Study Group.

Leuk Lymphoma. 2016 Dec;57(12):2777-2783. Epub 2016 Apr 18.

PMID:
27087066
17.

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF.

Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25.

PMID:
26687959
18.

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Leuk Lymphoma. 2016 May;57(5):1094-103. doi: 10.3109/10428194.2015.1079313. Epub 2015 Oct 12.

PMID:
26293000
19.

Radiotherapy in early stage follicular lymphoma: is it really the gold standard?

Janikova A.

Leuk Lymphoma. 2015;56(10):2999-3000. doi: 10.3109/10428194.2015.1049172. Epub 2015 Jun 18. No abstract available.

PMID:
25985811
20.

Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.

Chovancová J, Bernard T, Stehlíková O, Šálek D, Janíková A, Mayer J, Doubek M.

Cytometry B Clin Cytom. 2015 Mar;88(2):92-100. doi: 10.1002/cyto.b.21210. Epub 2015 Jan 14.

Supplemental Content

Loading ...
Support Center